J Nielsen1, L S Vestergaard2, L Richter3, D Schmid3, N Bustos4, T Asikainen4, R Trebbien2, G Denissov5, K Innos5, M J Virtanen6, A Fouillet7, T Lytras8, K Gkolfinopoulou8, M An der Heiden9, L Grabenhenrich9, H Uphoff10, A Paldy11, J Bobvos12, L Domegan13, J O'Donnell13, M Scortichini14, A de Martino15, J Mossong16, K England17, J Melillo18, L van Asten19, M Ma de Lange19, R Tønnessen20, R A White20, S P da Silva21, A P Rodrigues21, A Larrauri22, C Mazagatos22, A Farah23, A D Carnahan23, C Junker24, M Sinnathamby25, R G Pebody25, N Andrews25, A Reynolds26, J McMenamin26, C S Brown27, C Adlhoch28, P Penttinen28, K Mølbak29, T G Krause2. 1. Statens Serum Institut, Copenhagen, Denmark. Electronic address: nls@ssi.dk. 2. Statens Serum Institut, Copenhagen, Denmark. 3. Austrian Agency for Health and Food Safety, Vienna, Austria. 4. Sciensano, Brussels, Belgium. 5. National Institute for Health Development, Tallinn, Estonia. 6. Finnish National Institute for Health and Welfare, Helsinki, Finland. 7. French Public Health Agency (Santé Publique France), Saint-Maurice, France. 8. Hellenic Centre for Disease Control and Prevention, Athens, Greece. 9. Robert Koch Institute, Berlin, Germany. 10. Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. 11. National Public Health Institute, Budapest, Hungary. 12. Ministry of Human Capacities, Budapest, Hungary. 13. Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland. 14. Dipartimento Epidemiologia del S.S.R., Lazio - ASL Roma 1, Rome, Italy. 15. Ministero della Salute, Rome, Italy. 16. Laboratoire National de Santé, Luxembourg. 17. Directorate for Health Information and Research, Pieta, Malta. 18. Department of Health Regulation, Pieta, Malta. 19. National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. 20. Norwegian Institute of Public Health, Oslo, Norway. 21. Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal. 22. National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP), Carlos III Health Institute, Madrid, Spain. 23. Public Health Agency of Sweden, Stockholm, Sweden. 24. Federal Statistical Office, Neuchâtel, Switzerland. 25. Public Health England, Colindale, United Kingdom. 26. Health Protection Scotland, Glasgow, United Kingdom. 27. World Health Organization, Regional Office for Europe, Copenhagen, Denmark. 28. European Centre for Disease Prevention and Control, Solna, Sweden. 29. Statens Serum Institut, Copenhagen, Denmark; Department of Veterinary and Animal Science, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVES: Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high excess mortality during the influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe all-cause excess and influenza-attributable mortality during the season 2017/18 in Europe. METHODS: Based on weekly reporting of mortality from 24 European countries or sub-national regions, representing 60% of the European population excluding the Russian and Turkish parts of Europe, we estimated age stratified all-cause excess morality using the EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical and virological surveillance data, and adjusting for extreme temperatures. RESULTS: Excess mortality was mainly attributable to influenza activity from December 2017 to April 2018, but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The 2017/18 overall all-cause influenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per 100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this translates into over-all 152,000 deaths. CONCLUSIONS: The high mortality among elderly was unexpected in an influenza B dominated season, which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the common perception of influenza B only having a modest impact on excess mortality in the older population may need to be reconsidered.
OBJECTIVES: Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high excess mortality during the influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe all-cause excess and influenza-attributable mortality during the season 2017/18 in Europe. METHODS: Based on weekly reporting of mortality from 24 European countries or sub-national regions, representing 60% of the European population excluding the Russian and Turkish parts of Europe, we estimated age stratified all-cause excess morality using the EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical and virological surveillance data, and adjusting for extreme temperatures. RESULTS: Excess mortality was mainly attributable to influenza activity from December 2017 to April 2018, but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The 2017/18 overall all-cause influenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per 100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this translates into over-all 152,000 deaths. CONCLUSIONS: The high mortality among elderly was unexpected in an influenza B dominated season, which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the common perception of influenza B only having a modest impact on excess mortality in the older population may need to be reconsidered.
Authors: Florian Obendorf; Carmen Klammer; Matthias Heinzl; Margot Egger-Salmhofer; Michael Resl; Benjamin Dieplinger; Martin Clodi Journal: Wien Klin Wochenschr Date: 2019-11-27 Impact factor: 1.704
Authors: Péter Pál Böjti; Géza Szilágyi; Balázs Dobi; Rita Stang; István Szikora; Balázs Kis; Ákos Kornfeld; Csaba Óváry; Lóránd Erőss; Péter Banczerowski; Wojciech Kuczyński; Dániel Bereczki Journal: Geroscience Date: 2021-08-18 Impact factor: 7.713
Authors: Lasse S Vestergaard; Jens Nielsen; Lukas Richter; Daniela Schmid; Natalia Bustos; Toon Braeye; Gleb Denissov; Tatjana Veideman; Oskari Luomala; Teemu Möttönen; Anne Fouillet; Céline Caserio-Schönemann; Matthias An der Heiden; Helmut Uphoff; Theodore Lytras; Kassiani Gkolfinopoulou; Anna Paldy; Lisa Domegan; Joan O'Donnell; Francesca De' Donato; Fiammetta Noccioli; Patrick Hoffmann; Telma Velez; Kathleen England; Liselotte van Asten; Richard A White; Ragnhild Tønnessen; Susana P da Silva; Ana P Rodrigues; Amparo Larrauri; Concepción Delgado-Sanz; Ahmed Farah; Ilias Galanis; Christoph Junker; Damir Perisa; Mary Sinnathamby; Nick Andrews; Mark O'Doherty; Diogo Fp Marquess; Sharon Kennedy; Sonja J Olsen; Richard Pebody; Tyra G Krause; Kåre Mølbak Journal: Euro Surveill Date: 2020-07